# A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

Source: https://onco.cc/trials/nct07213817/  
OnCo record `nct07213817` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IPN60300 in advanced solid tumours, run by Ipsen, now recruiting.

## Summary

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours is a phase 1/2 interventional study registered as NCT07213817 by Ipsen, with 114 participants planned, started 2025-12-05 and due to reach its primary completion in 2028-10-30. Interventions recorded: IPN60300.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07213817
- Phase: 1/2
- Setting: An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumours.
- Sponsor: Ipsen
- Enrolled: 114

## Sources

- ClinicalTrials.gov NCT07213817: https://clinicaltrials.gov/study/NCT07213817

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Ipsen](https://onco.cc/companies/ipsen/)

---
JSON: https://onco.cc/api/v1/entities/nct07213817.json